Clonal blood mutations: how aging cells drive disease risk

Clonal hematopoiesis of indeterminate potential (CHIP) stands as one of the most consequential cellular mechanisms underlying human aging. When hematopoietic stem cells in bone marrow accumulate mutations in driver genes like DNMT3A, TET2, and TP53—genes classically tied to leukemia—these mutant variants gain a selective growth advantage and expand, progressively dominating the blood cell population. This clonal expansion, defined by more than two percent of peripheral blood cells arising from a single clone, not only disrupts the bone marrow microenvironment but also generates chronic inflammation that accelerates immune system deterioration. Epidemiological and experimental evidence link CHIP to cardiovascular and neurological disorders, though current human data establish risk association rather than definitive causality. For the longevity-focused clinician and biohacker, CHIP represents a new diagnostic window: identifying these clonal expansions enables intervention before they crystallize into disease, reframing what appeared inevitable aging into a potentially modifiable condition.